A quiet problem you never see
Imagine getting a tiny metal scaffold placed in an artery near the base of your skull to keep blood flowing to your brain. You feel better. Months pass. Then a scan shows the artery is narrowing again — inside the stent itself.
That's called in-stent restenosis (the artery re-narrowing inside a stent). And doctors have long wondered what to do next.
The vertebral artery runs up the back of your neck. It feeds the brainstem, the part of your brain that controls breathing, balance, and consciousness.
When it gets clogged, doctors sometimes place a stent at its opening, called the ostium. This helps prevent strokes. But the artery can narrow again, bringing symptoms back.
Until now, there wasn't much data on how to safely fix that second narrowing.
The old way vs a cleaner fix
Older stents were bare metal. They held the artery open but did nothing to stop scar tissue from growing through the mesh.
The newer tools are different. One is a drug-coated balloon (DCB), which inflates briefly and leaves behind medicine that slows scar growth. The other is a drug-eluting stent (DES), which releases medicine over time.
Here's the twist: we didn't really know how these tools performed when used as a second treatment on a stent that had already failed.
Think of the original stent like scaffolding around a building under repair. Over time, ivy (scar tissue) can grow through the scaffolding and block the doorway again.
A drug-coated balloon is like spraying the ivy with a growth blocker, then pulling the balloon out. Nothing new is left behind — just the medicine.
A drug-eluting stent is more like adding a second, smarter layer of scaffolding that slowly releases the growth blocker for months.
Both aim to keep the artery open longer than plain balloon angioplasty ever could.
The study in plain terms
Researchers at a single center tracked 525 patients who together received 564 stents in their vertebral artery openings. They followed them for an average of nearly 5 years.
Of those 564 stents, 89 (about 16%) narrowed again by more than half. Most of these re-narrowings were caught within the first year. The median time to detection was 7 months.
Re-treatment was performed 88 times. Doctors used a drug-eluting stent in 43% of cases and a drug-coated balloon in 57%.
No one had a stroke during the procedure. That's the most important safety number in a study like this.
But recurrence still happened. Another 19 of the re-treated arteries (about 1 in 5) narrowed again, on average about 2 years later.
Two lifestyle factors stood out as troublemakers: smoking and high cholesterol (dyslipidemia). Both were linked to the original narrowing and to the second one.
This fix is not a one-and-done promise.
The bigger picture
These findings line up with what heart specialists have been learning for years: drug-coated tools beat plain balloons for stopping scar regrowth.
The vertebral artery is a trickier place to work than a heart artery. It's narrower, more twisted, and closer to the brain. Getting through 88 re-treatments without a procedural stroke is a meaningful safety signal — though it happened at one experienced center.
If you've had a vertebral artery stent placed, ask your neurologist or interventional doctor about follow-up imaging. A second narrowing often shows up within the first year and may not cause symptoms at first.
If you smoke, this is another reason to quit. If your cholesterol is high, treating it aggressively may help keep your stent — and any future re-treatment — working longer.
This study doesn't change whether you should get a stent in the first place. It changes what happens if one starts to fail.
Where it falls short
This was a retrospective look at one hospital's experience with 525 patients. There was no comparison group randomly assigned to different treatments. So we can't say drug-eluting stents beat drug-coated balloons, or the other way around.
The team was highly experienced, which may be part of why the safety record was so strong. Results at less specialized centers could differ.
Larger, multicenter trials comparing drug-coated balloons head-to-head with drug-eluting stents would help settle which approach works best — and for which patients. Researchers also want to learn whether more aggressive cholesterol control or earlier smoking-cessation support can cut the recurrence rate below today's 1-in-5.
